Levetiracetam (All indications)

Study	Exclusion reasons	Rmk	Reference
Coste (Levetiracetam) (Controls unexposed, sick), 2020		EXCLUDED: this control group doesn't exist in the article (only in the report). Children with a diagnosis of brain malformation (ICD-10 codes Q00 to Q04 and Q05.0 to Q05.4) during their stay in the maternity unit are excluded.	Coste Sci Rep 2020; 10:17362 10.1038/s41598-020-74409-x
He (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
He (Levetiracetam) (Controls unexposed, sick), 2017	repeat population groups, duplicate reports (most recent study included)	Patients who developed epilepsy during pregnancy or after delivery were not included. Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023.	He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034
Meador (Levetiracetam) (Controls unexposed, disease free), 2021	repeat population groups, duplicate reports (most recent study included)	Overlapping: Meador 2021 and 2023 used the same cohort in order to study the same outcome, at 2 different ages (=> use of the data on the older children, i.e Meador 2023).	Meador JAMA Neurol 2021; 78:927-936 10.1001/jamaneurol.2021.1583
Meador (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2021	repeat population groups, duplicate reports (most recent study included)	Overlapping: Meador 2021 and 2023 used the same cohort in order to study the same outcome, at 2 different ages (=> use of the data on the older children, i.e Meador 2023).	Meador JAMA Neurol 2021; 78:927-936 10.1001/jamaneurol.2021.1583